AdvanCell Enters Into Strategic Collaboration with Lilly to Advance Novel Targeted Alpha Therapies for the Treatment of Cancer
10.2.2025 14:00:00 CET | Business Wire | Press release
AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, today announced an expansion to the scope and breadth of its strategic collaboration with Eli Lilly and Company to research and develop innovative treatments for various cancers.
Under this new agreement, the parties will leverage AdvanCell’s proprietary Pb-212 production technology and radionuclide development infrastructure and Lilly’s drug candidate programs and extensive expertise in drug development to facilitate the development and accelerate the clinical advancement of an expanded portfolio of targeted alpha therapies.
AdvanCell’s competitive advantage in technology development and the infrastructure it has built to accelerate early-stage clinical trials in Australia enables AdvanCell to rapidly develop and progress novel Pb-212-containing radiotherapeutics from discovery into clinical trials.
“This collaboration with Lilly represents a significant milestone for AdvanCell, recognizing our company as one of the leaders in the Pb-212 targeted alpha therapy space,” said Andrew Adamovich, CEO of AdvanCell. “By combining our groundbreaking isotope production capabilities, our team’s expertise and infrastructure with Lilly’s pharmaceutical and oncology expertise and global scale, we aim to bring transformative treatments to patients with hard-to-treat cancers. It is especially pleasing to continue and expand our existing relationship.”
Jacob Van Naarden, President of Lilly Oncology, added, “Partnering with AdvanCell aligns with our commitment to advancing innovative radiopharmaceuticals. We are excited to explore the potential of Pb-212-based alpha therapies as we work to bring meaningful new treatments for patients.”
Financial terms of the agreement were not disclosed.
About AdvanCell
AdvanCell is dedicated to developing innovative cancer therapies that harness the power of targeted alpha-emitting radionuclides. By combining advanced manufacturing capabilities with cutting-edge science and clinical development capabilities, AdvanCell aims to deliver novel treatments that improve outcomes for cancer patients globally. For more information, visit www.advancell.com.au.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250210990350/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Speech Processing Solutions Launches Philips SpeechLive Health, an AI Assistant Built for Modern Clinical Documentation17.3.2026 15:00:00 CET | Press release
Philips SpeechLive Health AI Assistant uses healthcare-trained AI to convert clinical conversations into structured notes, helping clinicians reduce administrative burden Speech Processing Solutions, the global leader in professional dictation and speech solutions sold under the Philips brand, today announced the upcoming April 2026 launch of Philips SpeechLive Health AI Assistant, an AI-powered clinical documentation assistant designed for healthcare professionals across multiple care settings. This solution reduces administrative burden, streamlines documentation, and improves provider and patient experiences. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317743584/en/ Philips SpeechLive Health AI Assistant turns clinical conversations into structured documentation, helping reduce administrative workload and create more time for patient care. Purpose-built for clinical documentation workflows Clinical workload remains
Moody’s Ratings Becomes First Credit Rating Agency to Bring Independent Credit Analysis to Blockchain Financial Infrastructure17.3.2026 15:00:00 CET | Press release
Moody’s Corporation (NYSE: MCO) today announced that Moody’s Ratings has launched its network-agnostic Token Integration Engine™ (TIE), becoming the first credit rating agency to ingest analytical data and share credit insights on-chain. As an inaugural step, it is the first rating agency to operate a node on the Canton Network. The milestone marks a significant step in Moody’s commitment to digital innovation, intending to enable secure, compliant, and efficient ingestion of data and dissemination of ratings enabled by technology built for integration across platforms. “As financial markets digitize, the need for independent, trusted risk analysis and credit insights does not change,” said Fabian Astic, Managing Director and Global Head of Digital Economy at Moody’s Ratings. “Moody’s Ratings is extending that rigor to digital market infrastructure consistent with global regulatory expectations and our governance, transparency, and compliance practices.” Moody’s Ratings’ TIE serves as
Coherent Solutions Releases Research on AI-driven Fraud Prevention in Banking and Finance and the Best AI Models for Banks17.3.2026 15:00:00 CET | Press release
Coherent Solutions has released a Future of Finance research illustrating how AI is advancing fraud detection in financial services. The research offers financial institutions a strategic framework to address rising and more sophisticated fraud techniques with adaptive, human-in-the-loop AI systems, based on the firm’s extensive experience in AI engineering. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317526196/en/ Coherent Solutions releases research on AI-driven fraud prevention. This white paper addresses the modern threat of transaction fraud, which is becoming faster and smarter while conventional rule-based systems lag, leaving financial institutions exposed. Banks, credit lenders, and financial institutions that adopt AI and machine learning can reduce fraud losses by up to 50% and detect anomalies in real time. When implemented with proper governance and human oversight, AI systems also make audits smoother and
The Swoosh Meets the ‘b’: Beats and Nike Unveil Historic First-Ever Collaboration for Powerbeats Pro 217.3.2026 15:00:00 CET | Press release
LeBron James trades the court for the course in a star-studded campaign celebrating the ultimate performance crossover Today, Beats and Nike announced the first hardware collaboration in their shared history: Powerbeats Pro 2 – Nike Special Edition. In a landmark design shift, Beats has—for the first time—shared its iconic earbud real estate with a partner, featuring the Nike Swoosh on the right bud and the signature Beats “b” on the left. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317159868/en/ Powerbeats Pro 2 - Nike Special Edition The limited-edition release marries Nike’s high-energy “Volt” color palette with the industry-leading audio tech of the Powerbeats Pro 2. The result is a performance tool built to bridge the gap between elite sport and street style. The Nike Special Edition arrives in a striking matte black, Volt-speckled charging case. Upon opening, users are greeted by Nike’s “JUST DO IT” mantra printe
Sub-Q Bionics Announces Licensing Agreement to Advance Lymphedema Care17.3.2026 14:46:00 CET | Press release
Sub‑Q Bionics, a medical device company developing an innovative implantable lymphatic drainage system designed to help patients living with lymphedema better manage their symptoms, today announced a licensing agreement with Mayo Clinic. Through the agreement, Sub-Q Bionics has licensed clinical know-how from Mayo Clinic related to reconstructive and lymphatic surgery. As part of this collaboration, Vahe Fahradyan, M.D., a plastic and reconstructive surgeon with expertise in lymphatic surgery, plans to work with Sub-Q Bionics as a clinical collaborator supporting the company’s ongoing development activities. Lymphedema is a chronic condition caused by impaired lymphatic drainage that can lead to persistent swelling, discomfort, and reduced mobility. It commonly occurs following cancer treatment, particularly among breast cancer survivors. Sub-Q Bionics is developing the world’s first implantable bionic lymphatic drainage system designed to assist with movement of lymphatic fluid and he
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom